STOCK TITAN

IntelGenx Technologies Corp - IGXT STOCK NEWS

Welcome to our dedicated news page for IntelGenx Technologies (Ticker: IGXT), a resource for investors and traders seeking the latest updates and insights on IntelGenx Technologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IntelGenx Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IntelGenx Technologies's position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.75%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
conferences earnings
Rhea-AI Summary
IntelGenx Corp. has completed patient enrollment in the Montelukast VersaFilm Phase 2a clinical trial for Alzheimer's Disease. The study enrolled 52 patients, 18 fewer than planned, with approval from Health Canada. The company aims to determine the extent of the drug's effect sizes and expects to complete the trial in Q1 2024 and report initial results in Q2 2024. The AD market is projected to reach $13.7 billion in 2030 with a compound annual growth rate of 20%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.88%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Rhea-AI Summary
IntelGenx Technologies Corp. announces that shareholders voted in favor of all items of business at the annual meeting. The meeting was held virtually and had a majority of shareholders present. The voting results for the election of directors were also provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
none
Rhea-AI Summary
IntelGenx Technologies Corp. reported financial results for Q1 2023. Revenue was $162,000, net comprehensive loss was $2.9 million, and adjusted EBITDA loss was $2.4 million. The company received FDA approval for its RIZAFILM® VersaFilm® for acute migraine treatment. Various changes were made to the management team. IntelGenx entered into research collaborations and supply agreements. The company's cash and short-term investments totaled $3.8 million as of March 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
IntelGenx Technologies Corp

OTC:IGXT

IGXT Rankings

IGXT Stock Data

32.33M
135.32M
22.4%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Saint Laurent

About IGXT

intelgenx is a montreal based company devoted to developing its novel and innovative proprietary technologies for enhanced drug delivery. our business strategy is to apply our proprietary drug delivery technologies to improve existing drug compounds with proven efficacy and safety and, in conjunction with strategic development and distribution partners, reintroduce these drug compounds to the market as branded products with improved deliverability and efficacy. intelgenx is capable, through itself and strategic partners, of offering its partners full service pharmaceutical development from formulation development, clinical development and regulatory activities to manufacturing and packaging. intelgenx’s highly qualified team has the capability to work with new chemical entities (nces) or established therapeutic active pharmaceutical ingredients (apis) where the use of innovative new drug delivery systems offer significant competitive advantage or the opportunity for product exten